Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07745101

Research On Advanced Diagnostics and Management of All Pregnancies to Prevent Stillbirth (ROADMAPS)

The primary objective of the Stillbirth Research Consortium (SBRC) longitudinal cohort study is to develop and evaluate a robust multivariable prediction model to identify pregnancies at <14 weeks gestation that are at increased risk of stillbirth or fetal growth restriction (FGR), often reflecting underlying placental dysfunction.

Secondary objectives include:

* To evaluate placental pathology among cases and selected controls using standardized Amsterdam criteria. * To identify key aspects of perinatal nutrition contributing to placental dysfunction * To determine relationships between maternal biomarkers, placental pathology and energetics, with the goal of identifying biomarkers predictive of placental dysfunction * To develop a risk stratification model for pregnancies complicated by decreased fetal movements (DFM)

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

University of California Center for Stillbirth Prevention, San Diego, California, United States

Loading trial locations.

About this study

In the United States, stillbirth defined as fetal death at or beyond 20 weeks' gestation affects approximately 5.48/1,000 births, or 1 in 180 pregnancies, a rate that surpasses many other high-resource countries, highlighting major opportunities for improvement and prevention. Prevention of stillbirth in the United States requires improved risk stratification to identify pregnancies at highest risk. Unfortunately, commonly used pre-pregnancy risk factors such as parity, advanced maternal age, and body mass index are poor predictors of stillbirth and explain only a small proportion of stillbirth risk. Critical gaps in stillbirth risk stratification hamper efforts to accurately identify at-risk pregnancies early enough to enable effective interventions and ultimately reduce stillbirth and those on the path to stillbirth.

FGR is frequently a manifestation of underlying placental dysfunction and one of the strongest known risk factors for stillbirth, with a stillbirth rate of 1.5% (two-fold increased risk). FGR, defined as a fetus that fails to reach its growth potential, is difficult to diagnose. The term small for gestational age, defined as estimated or actual birthweight below the 10th percentile, is often used interchangeably with FGR, although it does not distinguish between constitutionally small fetuses and those affected by pathologic growth restriction.

Early onset FGR is well recognized as a major risk factor for stillbirth, yet nearly half of FGR fetuses are not detected antenatally. The development of abnormal fetal umbilical artery (UA) Doppler indices differentiates between constitutionally small fetuses and those with increased risk of stillbirth. Estimated fetal weight below the 3rd percentile has been associated with a further increased risk of adverse perinatal outcome irrespective of Doppler indices (3-fold risk over 3rd to 5th percentile, and 4- to 7-fold risk over 5th to 10th percentile).

To address the need for more timely identification of pregnancies at risk for stillbirth or FGR, we will conduct a longitudinal prospective cohort study to develop a prediction model to identify pregnancies at <14 weeks gestation with increased risk of stillbirth or severe FGR. We will use the Hadlock nomogram to define birthweight percentile since we seek to identify at-risk pregnancies prenatally.

Placental Dysfunction

Placental dysfunction is a central biological pathway underlying both FGR and many stillbirths. It reflects the inability of the placenta to meet the metabolic demands of a growing fetus. However, placental dysfunction is heterogenous and difficult to diagnose during an ongoing pregnancy. Post delivery, placental dysfunction can be identified following a complete pathologic evaluation, using standardized pathologic criteria, including maternal vascular malperfusion (MVM), fetal vascular malperfusion (FVM), inflammatory villitis of unknown etiology (VUE) or acute chorioamnionitis (ACA) patterns of injury, or as Massive Perivillous Fibrin Deposition/Maternal Floor Infarction (MPVFD/MFI) as defined by the Amsterdam Workshop Guidelines.

Despite advances in placental pathology, there are currently no validated biomarkers that can reliably identify placental dysfunction during pregnancy. The placenta generates and utilizes considerable energy to support its own function consuming half of the oxygen and nutrients supplied to the pregnant uterus. Measurement of trophoblast energetics in vitro post-delivery allows assessment into placental "health" and ability to support the fetus.

To address the need for more timely identification of pregnancies at risk for stillbirth and FGR, we will utilize innovative placental imaging and biomarkers to examine early indicators of placental dysfunction before 14 weeks' gestation and their association with stillbirth and severe FGR (Secondary Objective).

Perinatal Nutrition

Perinatal nutrition is a potentially modifiable factor that influences placental function and pregnancy outcomes. Higher diet quality has been associated with lower allostatic load, while suboptimal perinatal nutrition is associated with stillbirth and adverse pregnancy outcomes. Nutritional status is critical for the health of the pregnant individual, placental function, and developing offspring. By understanding the role of nutrition in pregnancy outcomes, we will be able to better identify high-risk individuals and potential interventions.

Decreased Fetal Movements

DFM are generally assessed as part of standard care; however, assessment and management vary widely, and evidence regarding their predictive value is inconsistent. Within this cohort, we will collect standardized data on fetal movements and evaluate their association with adverse outcomes. These data will be used to develop a risk stratification framework and inform best practices for the clinical management of DFM.

Together, achieving these objectives will provide a better understanding of these factors will provide robust information to inform clinical practice to improve birth outcomes in the United States.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Early Pregnancy Cohort Inclusion Criteria

  • 18 years of age
  • Gestational age at enrollment: Between 12.0 and 13.6 weeks of gestation
  • Pregnant individuals receiving care at participating clinical sites with intent of delivering at study hospital
  • Consent to participate in study procedures through 6 weeks postpartum

Late Pregnancy Cohort

  • 18 years or older
  • Gestational age at enrollment: greater than or equal to 28.0 weeks gestational age
  • Clinical indications of risk FGR <10th percentile or report of decreased fetal movement)
  • Pregnant individual receiving care at participating clinical sites with intent of delivering at study hospital
  • Consent to participate in study procedures through 6 weeks postpartum

Exclusion criteria

  • Evidence of fetal genetic anomaly or major structural malformation
  • Known fetal aneuploidy based on chorionic villus sampling
  • Positive cell-free fetal DNA screening for aneuploidy
  • Multifetal gestation
  • Less than 18 years of age
  • Not fluent in either English or Spanish

Treatment and study plan

Primary outcomes

  1. The primary outcome is a composite outcome of stillbirth or severe placental dysfunction, defined as the occurrence of birth at or beyond 20.0 weeks of gestation.

    Time frame: 7 days post delivery

    Stillbirth, Fetal Growth Restriction (FGR) or Neonatal Mortality <7 days among births at ≥20.0 weeks' gestation meeting one or more of the following:

    • Stillbirth among births at >20.0 weeks' gestation
    • FGR defined as:

    FGR < 3rd percentile

    FGR 3 - <10th percentile with at least one of the following criteria:

    Umbilical artery Doppler > 95th percentile for either systolic/diastolic ratio (S/D), pulsatility index (PI), or resistance index (RI) Oligohydramnios Non-reassuring fetal heart rate or biophysical profile

    • Neonatal death less than or equal to 7 days, excluding non-medical causes

    Primary outcome Time Frame: Birth through 7-days post delivery

Secondary outcomes

  1. Stillbirth

    Time frame: Delivery

    Stillbirth among all births

  2. Fetal growth restriction (FGR)

    Time frame: Delivery

    Fetal growth restriction <10%ile with at least one of the following criteria:

    • Umbilical artery Doppler > 95th percentile for either systolic/diastolic ratio (S/D), pulsatility index (PI), or resistance index (RI)
    • Oligohydramnios
    • Non-reassuring fetal heart rate or biophysical profile
  3. Neonatal mortality

    Time frame: Up to 7 days after delivery

    Early neonatal mortality among live births

  4. Placental dysfunction among stillbirths, fetal growth restriction and neonatal deaths

    Time frame: Delivery

    Placental dysfunction will be defined using the Amsterdam Criteria including the following characteristics: Maternal vascular malperfusion (MVM), fetal vascular malperfusion (FVM), VUE, or MPVFD/MFI; other important findings associated with placental insufficiency; and/or cord abnormalities associated with placental insufficiency

  5. Cause of stillbirth

    Time frame: Delivery

    Classification of cause of stillbirth using published classification system

  6. Apgar score

    Time frame: Delivery

    Among fetal growth restriction (<10th%ile) infants, 5-minute Apgar score

  7. Neurologic injury

    Time frame: Birth to 7 days

    Evidence of neurologic injury among infants with severe FGR

  8. Hypoxic-ischemic encephalopathy (HIE)

    Time frame: Birth to 7 days

    HIE based on the Sarnat examination among infants with severe fetal growth restriction.

  9. Intraventricular hemorrhage

    Time frame: delivery

    Diagnosis of intraventricular hemorrhage among infants with severe fetal growth restricition.

  10. Hypotension

    Time frame: Birth to 7 days

    Hypotension requiring vasopressor or inotrope for cardiovascular support among infants with severe fetal growth restriction

  11. Cord arterial blood gas

    Time frame: Birth to 7 days

    Cord arterial blood gas demonstrating pH <7.0 or base excess > 12 mEq/L among infants with severe fetal growth restriction

  12. Seizures

    Time frame: Birth to 7 days

    Neonatal seizures among infants with severe fetal growth restriction

  13. Gestational age at delivery

    Time frame: Delivery

    Estimated gestational age at delivery based on early ultrasound among infants with severe fetal growth restriction.

  14. Days admitted to the Neonatal Intensive Care Unit (NICU)

    Time frame: Birth to day 28

    Number days admitted to the NICU among infants with severe fetal growth restriction

  15. Neonatal mortality

    Time frame: Birth to 28 days post-delivery

    Neonaal death (<=28 days) among infants with severe fetal growth restriction.

Study contacts

Contact information is provided by the study sponsor or research team.

Carla Bann, PhD

CONTACT

[email protected]

919-485-2773

Elizabeth McClure, PhD

CONTACT

[email protected]

919-316-3773

Sponsors and collaborators

Lead sponsor

RTI International

Other

Collaborators

  • Columbia University
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Old Dominion University
  • Oregon Health and Science University
  • University of California, San Diego
  • University of Utah

Registry information

Official study title

NICHD Stillbirth Research Consortium: Research on Advanced Diagnostics and Management of All Pregnancies to Prevent Stillbirth (ROADMAPS)

Acronym: ROADMAPS

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Aug 4, 2026
Registry last updated
Aug 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.